Clinical Activity and Safety of Anlotinib Combined with PD-1 Blockades for Patients with Previously Treated Small Cell Lung Cancer

References

• Calles A, Aguado G, Sandoval C, Álvarez R. The role of immunotherapy in small cell lung cancer. Clin Transl Oncol. 2019;21(8):961–976. doi:10.1007/s12094-018-02011-9
   PubMed Web of Science ®Google Scholar
• Guo H, Wei J, Li X, et al. Do socioeconomic factors modify the effects of PM1 and SO2 on lung cancer incidence in China? Sci Total Environ. 2021;756:143998. doi:10.1016/j.scitotenv.2020.143998
   PubMed Web of Science ®Google Scholar
• Wang Y, Zou S, Zhao Z, et al. New insights into small-cell lung cancer development and therapy. Cell Biol Int. 2020;44(8):1564–1576. doi:10.1002/cbin.11359
   PubMed Web of Science ®Google Scholar
• Hart LL, Ferrarotto R, Andric ZG, et al. Myelopreservation with trilaciclib in patients receiving topotecan for small cell lung cancer: results from a randomized, double-blind, placebo-controlled phase II study. Adv Ther. 2021;38(1):350–365. doi:10.1007/s12325-020-01538-0
   PubMed Web of Science ®Google Scholar
• Chen P, Zhu J, Liu DY, et al. Over-expression of survivin and VEGF in small-cell lung cancer may predict the poorer prognosis. Med Oncol. 2014;31(1):775. doi:10.1007/s12032-013-0775-5
   PubMed Web of Science ®Google Scholar
• Montanino A, Manzo A, Carillio G, et al. Angiogenesis inhibitors in small cell lung cancer. Front Oncol. 2021;11:655316. doi:10.3389/fonc.2021.655316
   PubMed Web of Science ®Google Scholar
• Cheng Y, Wang Q, Li K, et al. Anlotinib vs placebo as third- or further-line treatment for patients with small cell lung cancer: a randomised, double-blind, placebo-controlled Phase 2 study. Br J Cancer. 2021;125(3):366–371. doi:10.1038/s41416-021-01356-3
   PubMed Web of Science ®Google Scholar
• Robin TP, Rusthoven CG. Radiosurgery for small-cell lung cancer brain metastases: a review. J Thorac Dis. 2020;12(10):6234–6239. doi:10.21037/jtd.2020.03.90
   PubMed Web of Science ®Google Scholar
• Ogino A, Choi J, Lin M, et al. Genomic and pathological heterogeneity in clinically diagnosed small cell lung cancer in never/light smokers identifies therapeutically targetable alterations. Mol Oncol. 2021;15(1):27–42. doi:10.1002/1878-0261.12673
   PubMed Web of Science ®Google Scholar
• Horn L, Mansfield AS, Szczesna A, et al. First-line atezolizumab plus Chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379(23):2220–2229. doi:10.1056/NEJMoa1809064
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, Phase 3 trial. Lancet. 2019;394(10212):1929–1939. doi:10.1016/s0140-6736(19)32222-6
   PubMed Web of Science ®Google Scholar
• Lim JU, Kang HS. A narrative review of current and potential prognostic biomarkers for immunotherapy in small-cell lung cancer. Ann Transl Med. 2021;9(9):809. doi:10.21037/atm-21-68
   PubMed Web of Science ®Google Scholar
• Huang W, Chen JJ, Xing R, Zeng YC. Combination therapy: future directions of immunotherapy in small cell lung cancer. Transl Oncol. 2021;14(1):100889. doi:10.1016/j.tranon.2020.100889
   PubMed Web of Science ®Google Scholar
• Song Y, Fu Y, Xie Q, et al. Anti-angiogenic agents in combination with immune checkpoint inhibitors: a promising strategy for cancer treatment. Front Immunol. 2020;11:1956. doi:10.3389/fimmu.2020.01956
   PubMed Web of Science ®Google Scholar
• Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894–1905. doi:10.1056/NEJMoa1915745
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247. doi:10.1016/j.ejca.2008.10.026
   PubMed Web of Science ®Google Scholar
• Miller TP, Fisher BT, Getz KD, et al. Unintended consequences of evolution of the common terminology criteria for adverse events. Pediatr Blood Cancer. 2019;66(7):e27747. doi:10.1002/pbc.27747
   PubMed Web of Science ®Google Scholar
• Zhang X, Zeng L, Li Y, et al. Anlotinib combined with PD-1 blockade for the treatment of lung cancer: a real-world retrospective study in China. Cancer Immunol Immunother. 2021;70(9):2517–2528. doi:10.1007/s00262-021-02869-9
   PubMed Web of Science ®Google Scholar
• Stratigos M, Matikas A, Voutsina A, Mavroudis D, Georgoulias V. Targeting angiogenesis in small cell lung cancer. Transl Lung Cancer Res. 2016;5(4):389–400. doi:10.21037/tlcr.2016.08.04
   PubMed Web of Science ®Google Scholar
• de Jong WK, Ten Hacken NH, Groen HJ. Third-line chemotherapy for small cell lung cancer. Lung Cancer. 2006;52(3):339–342. doi:10.1016/j.lungcan.2006.02.005
   PubMed Web of Science ®Google Scholar
• Morgensztern D, Besse B, Greillier L, et al. Efficacy and safety of rovalpituzumab tesirine in third-line and beyond patients with DLL3-expressing, relapsed/refractory small-cell lung cancer: results from the phase II TRINITY study. Clin Cancer Res. 2019;25(23):6958–6966. doi:10.1158/1078-0432.ccr-19-1133
   PubMed Web of Science ®Google Scholar
• Lin B, Song X, Yang D, et al. Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRbeta and FGFR1. Gene. 2018;654:77–86. doi:10.1016/j.gene.2018.02.026
   PubMed Web of Science ®Google Scholar
• Sun Y, Niu W, Du F, et al. Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors. J Hematol Oncol. 2016;9(1):105. doi:10.1186/s13045-016-0332-8
   PubMed Web of Science ®Google Scholar
• Ying cheng Y, Wang Q, Li K, et al. OA13.03 Anlotinib as third-line or further-line treatment in relapsed SCLC: a multicentre, randomized, double-blind phase 2 trial. J Thorac Oncol. 2018;13(10):S351–S352. doi:10.1016/j.jtho.2018.08.308
   Web of Science ®Google Scholar
• Chung HC, Piha-Paul SA, Lopez-Martin J, et al. Pembrolizumab after two or more lines of previous therapy in patients with recurrent or metastatic SCLC: results from the KEYNOTE-028 and KEYNOTE-158 studies. J Thorac Oncol. 2020;15(4):618–627. doi:10.1016/j.jtho.2019.12.109
   PubMed Web of Science ®Google Scholar
• Antonia SJ, López-Martin JA, Bendell J, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, Phase 1/2 trial. Lancet Oncol. 2016;17(7):883–895. doi:10.1016/s1470-2045(16)30098-5
   PubMed Web of Science ®Google Scholar
• Ott PA, Elez E, Hiret S, et al. Pembrolizumab in patients with extensive-stage small-cell lung Cancer: results from the phase Ib KEYNOTE-028 study. J Clin Oncol. 2017;35(34):3823–3829. doi:10.1200/jco.2017.72.5069
   PubMed Web of Science ®Google Scholar
• Ardizzoni A, Hansen H, Dombernowsky P, et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for research and treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. J Clin Oncol. 1997;15(5):2090–2096. doi:10.1200/jco.1997.15.5.2090
   PubMed Web of Science ®Google Scholar
• Trigo J, Subbiah V, Besse B, et al. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. Lancet Oncol. 2020;21(5):645–654. doi:10.1016/s1470-2045(20)30068-1
   PubMed Web of Science ®Google Scholar
• Fan Y, Zhao J, Wang Q, et al. Camrelizumab plus apatinib in extensive-stage SCLC (PASSION): a multicenter, two-stage, phase 2 trial. J Thorac Oncol. 2021;16(2):299–309. doi:10.1016/j.jtho.2020.10.002
   PubMed Web of Science ®Google Scholar
• Foster NR, Mandrekar SJ, Schild SE, et al. Prognostic factors differ by tumor stage for small cell lung cancer: a pooled analysis of North Central Cancer Treatment Group trials. Cancer. 2009;115(12):2721–2731. doi:10.1002/cncr.24314
   PubMed Web of Science ®Google Scholar
• Rades D, Motisi L, Veninga T, et al. Predictors of outcomes and a scoring system for estimating survival in patients treated with radiotherapy for metastatic spinal cord compression from small-cell lung cancer. Clin Lung Cancer. 2019;20(4):322–329. doi:10.1016/j.cllc.2019.04.005
   PubMed Web of Science ®Google Scholar
• Wang S, Hu C, Xie F, Liu Y. Use of programmed death receptor-1 and/or programmed death ligand 1 inhibitors for the treatment of brain metastasis of lung cancer. Onco Targets Ther. 2020;13:667–683. doi:10.2147/ott.s235714
   PubMed Web of Science ®Google Scholar
• Berghoff AS, Ricken G, Wilhelm D, et al. Tumor infiltrating lymphocytes and PD-L1 expression in brain metastases of small cell lung cancer (SCLC). J Neurooncol. 2016;130(1):19–29. doi:10.1007/s11060-016-2216-8
   PubMed Web of Science ®Google Scholar
• Wu D, Nie J, Hu W, et al. A phase II study of anlotinib in 45 patients with relapsed small cell lung cancer. Int J Cancer. 2020;147(12):3453–3460. doi:10.1002/ijc.33161
   PubMed Web of Science ®Google Scholar
• Wang F, Qin S, Sun X, et al. Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial. J Hematol Oncol. 2020;13(1):47. doi:10.1186/s13045-020-00886-2
   PubMed Web of Science ®Google Scholar
• Jiang FE, Zhang HJ, Yu CY, Liu AN. Efficacy and safety of regorafenib or fruquintinib plus camrelizumab in patients with microsatellite stable and/or proficient mismatch repair metastatic colorectal cancer: an observational pilot study. Neoplasma. 2021;68(4):861–866. doi:10.4149/neo_2021_201228N1415
   PubMed Web of Science ®Google Scholar